AU2008232354B9 - Triazinone and diazinone derivatives useful as Hsp90 inhibitors - Google Patents

Triazinone and diazinone derivatives useful as Hsp90 inhibitors Download PDF

Info

Publication number
AU2008232354B9
AU2008232354B9 AU2008232354A AU2008232354A AU2008232354B9 AU 2008232354 B9 AU2008232354 B9 AU 2008232354B9 AU 2008232354 A AU2008232354 A AU 2008232354A AU 2008232354 A AU2008232354 A AU 2008232354A AU 2008232354 B9 AU2008232354 B9 AU 2008232354B9
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
independently
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008232354A
Other languages
English (en)
Other versions
AU2008232354B2 (en
AU2008232354A1 (en
Inventor
Zhenjian Du
Kevin Foley
Chi-Wan Lee
Teresa Przewloka
Shuzhen Qin
Minghu Song
Weiwen Ying
Dan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2008232354A1 publication Critical patent/AU2008232354A1/en
Application granted granted Critical
Publication of AU2008232354B2 publication Critical patent/AU2008232354B2/en
Publication of AU2008232354B9 publication Critical patent/AU2008232354B9/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008232354A 2007-03-27 2008-03-24 Triazinone and diazinone derivatives useful as Hsp90 inhibitors Ceased AU2008232354B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92032707P 2007-03-27 2007-03-27
US60/920,327 2007-03-27
PCT/US2008/003810 WO2008118391A2 (en) 2007-03-27 2008-03-24 Triazinone and diazinone derivatives useful as hsp90 inhibitors

Publications (3)

Publication Number Publication Date
AU2008232354A1 AU2008232354A1 (en) 2008-10-02
AU2008232354B2 AU2008232354B2 (en) 2012-06-28
AU2008232354B9 true AU2008232354B9 (en) 2012-07-26

Family

ID=39739347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008232354A Ceased AU2008232354B9 (en) 2007-03-27 2008-03-24 Triazinone and diazinone derivatives useful as Hsp90 inhibitors

Country Status (9)

Country Link
US (2) US8524712B2 (enExample)
EP (1) EP2155694B1 (enExample)
JP (1) JP5529004B2 (enExample)
AT (1) ATE540028T1 (enExample)
AU (1) AU2008232354B9 (enExample)
CA (1) CA2682665C (enExample)
ES (1) ES2395114T3 (enExample)
TW (1) TWI427068B (enExample)
WO (1) WO2008118391A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52642B (sr) 2004-11-18 2013-06-28 Synta Pharmaceuticals Corp. Jedinjenja triazola koja modulišu aktivnost hsp90
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
EP2034996A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Triazole compounds that modulate hsp90 activity
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
EP2032545A2 (en) * 2006-05-25 2009-03-11 Synta Pharmaceuticals Corporation Compounds that modulate hsp90 activity and methods for identifying same
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
WO2009158026A1 (en) 2008-06-27 2009-12-30 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate hsp90 activity
WO2010017479A1 (en) * 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
EP2452940B1 (en) * 2009-07-10 2014-12-17 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
JP5775519B2 (ja) 2009-09-25 2015-09-09 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規ジヒドロピリミジン−２（１ｈ）−オン化合物
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US8906933B2 (en) 2010-09-24 2014-12-09 N30 Pharmaceuticals, Inc. Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
WO2013006864A2 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
PH12014500168A1 (en) * 2011-07-27 2014-02-24 Ab Science Selective protein kinase inhibitors
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
JP6835709B2 (ja) 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法
WO2018049092A1 (en) * 2016-09-09 2018-03-15 University Of Cincinnati Small molecule prolactin receptor inhibitors, pharmaceutical compositions and treatment methods using such inhibitors
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN109666024A (zh) * 2018-03-20 2019-04-23 兰州大学 2-氧嘧啶类化合物及其制备方法和用途
CN110105365B (zh) * 2019-05-29 2021-08-10 华中农业大学 一种喹啉衍生物VCTb5及其在制备抗癌药物中的应用
CN110105366B (zh) * 2019-05-29 2021-06-01 华中农业大学 一种喹啉衍生物VCTb9及其在制备抗癌药物中的应用
KR20230035049A (ko) * 2020-07-02 2023-03-10 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
WO2025188973A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000300A1 (en) * 2003-06-27 2005-01-06 Vernalis (Cambridge) Limited Substituted 5-membered ring compounds and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239540A1 (de) * 1992-11-25 1994-05-26 Asta Medica Ag Neue heterocyclische Verbindungen mit antiasthmatischer/antiallergischer, entzündungshemmender, positiv inotroper und blutdrucksenkender Wirkung
GB0320300D0 (en) * 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
EP1736472A4 (en) * 2004-04-15 2007-10-31 Astellas Pharma Inc 2-aminopyridine derivative
CN101189214A (zh) * 2005-05-03 2008-05-28 美国陶氏益农公司 取代的4，5-二氢-1，2，4-三嗪-6-酮、1，2，4-三嗪-6-酮及其作为杀菌剂的用途
JP2008540626A (ja) * 2005-05-19 2008-11-20 アステックス、セラピューティックス、リミテッド 医薬化合物
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000300A1 (en) * 2003-06-27 2005-01-06 Vernalis (Cambridge) Limited Substituted 5-membered ring compounds and their use

Also Published As

Publication number Publication date
CA2682665A1 (en) 2008-10-02
TWI427068B (zh) 2014-02-21
WO2008118391A2 (en) 2008-10-02
US8524712B2 (en) 2013-09-03
JP5529004B2 (ja) 2014-06-25
AU2008232354B2 (en) 2012-06-28
US20130345219A1 (en) 2013-12-26
TW200846329A (en) 2008-12-01
JP2010522750A (ja) 2010-07-08
AU2008232354A1 (en) 2008-10-02
ATE540028T1 (de) 2012-01-15
EP2155694A2 (en) 2010-02-24
US20100298331A1 (en) 2010-11-25
EP2155694B1 (en) 2012-01-04
WO2008118391A3 (en) 2008-12-18
ES2395114T3 (es) 2013-02-08
CA2682665C (en) 2015-07-21

Similar Documents

Publication Publication Date Title
AU2008232354B9 (en) Triazinone and diazinone derivatives useful as Hsp90 inhibitors
EP2118077B1 (en) Triazole compounds that modulate hsp90 activity
EP2038262B1 (en) Triazole compounds that modulate hsp90 activity
AU2008287367B2 (en) Triazole compounds that modulate HSP90 activity
EP2035396B1 (en) Triazole compounds that modulate hsp90 activity
EP2328893B1 (en) Triazole compounds that modulate hsp90 activity
US9156836B2 (en) Tricyclic triazole compounds that modulate HSP90 activity
US20110144103A1 (en) Pyrrole compounds that modulate hsp90 activity
CA2868258A1 (en) Triazole derivatives as hsp90 inhibitors
HK1137455B (en) Triazole compounds that modulate hsp90 activity

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired